Stay updated with breaking news from Lon Avct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Avacta Group Plc (LON:AVCT – Get Rating) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 124.79 ($1.53) and traded as low as GBX 113.50 ($1.39). Avacta Group shares last traded at GBX 114.50 ($1.41), with a volume […]
28 May 2021 | 09:46am StockMarketWire.com - Cancer therapies and diagnostics Avacta said it had yet to receive any update from the UK Medicines and Healthcare products Regulatory Agency on the CE mark submission for its SARS-CoV-2 antigen lateral flow test. Its partner, Mologic Limited had filed the CE application. 'To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so,' the company said. At 9:46am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p Story provided by StockMarketWire.com Find out ...
6 April 2021 | 09:26am StockMarketWire.com - Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents. Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue. At 9:26am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p Story provided by StockMarketWire.com Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account....
Avacta signs diagnostic licensing deal with Biokit
Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021